Showing results (1041-1050 of 2,413) with videos related to
Sort By:
Pageof 242
Journal of Medical Economics|July 17, 2020
A comparison of partitioned survival analysis and state transition multi-state modelling approaches using a case study in oncologyHolly Cranmer, Gemma E Shields, Ash BullementJournal of Medical Economics|March 25, 2015
Treatment cost of non-small cell lung cancer in three European countries: comparisons across France, Germany, and England using administrative databasesA McGuire, M Martin, C Lenz, et al.Journal of Medical Economics|April 9, 2015
Inhaled nitric oxide in term/late preterm neonates with hypoxic respiratory failure: estimating the financial impact of earlier useG Ganesh Konduri, Joseph Menzin, Molly Frean, et al.Journal of Medical Economics|April 9, 2015
Cost-effectiveness of once daily GLP-1 receptor agonist lixisenatide compared to bolus insulin both in combination with basal insulin for the treatment of patients with type 2 diabetes in NorwayPernilla Huetson, James L Palmer, Andrée Levorsen, et al.Journal of Medical Economics|July 14, 2020
Use of real-world evidence in meta-analyses and cost-effectiveness modelsKevin Bowrin, Jean-Baptiste Briere, Pierre Levy, et al.Journal of Medical Economics|August 5, 2020
Real-world cost-effectiveness of insulin degludec in type 1 and type 2 diabetes mellitus from a Swedish 1-year and long-term perspectiveJohan Jendle, Åsa Ericsson, Bertil Ekman, et al.Journal of Medical Economics|July 19, 2012
Elicitation of health state utilities associated with differing durations of morning stiffness in rheumatoid arthritisI Iqbal, B Dasgupta, P Taylor, et al.Journal of Medical Economics|October 10, 2012
Cost-effectiveness analysis of pancreatin minimicrospheres in patients with pancreatic exocrine insufficiency due to chronic pancreatitisJ H Morawski, A Prüfert, A van Engen, et al.Journal of Medical Economics|October 6, 2012
Cost-effectiveness of denosumab in the treatment of postmenopausal osteoporosis in CanadaD Chau, D L Becker, M E Coombes, et al.Journal of Medical Economics|October 6, 2012
Cost analysis of the treatments for patients with advanced Parkinson's disease: SCOPE studyFrancesc Valldeoriola, Jaume Puig-Junoy, Ruth Puig-Peiró, et al.Pageof 242